Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDXK | O00764 | 1/20 | 0.33 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22902576 | 0.80 | IKBKB (0.44) | KDM4EALDH1A1PDXKKMT2AMEN1 | |
| SCHEMBL29790092 | 0.80 | IKBKB (0.44) | KDM4EALDH1A1PDXKKMT2AMEN1 | |
| SCHEMBL28972297 | 0.79 | SMN1; SMN2 (0.39) | KDM4EALDH1A1KMT2AMEN1HTT | |
| SCHEMBL22696331 | 0.79 | SMN1; SMN2 (0.39) | KDM4EALDH1A1KMT2AMEN1HTT | |
| SCHEMBL6441695 | 0.78 | PDXK (0.35) | CYP2D6CYP2C19KDM4EALDH1A1PDXK | |
| SCHEMBL903627 | 0.77 | PDXK (0.42) | CYP2D6CYP2C19KDM4EALDH1A1PDXK | |
| SCHEMBL8037329 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1KMT2AHTTIKBKB | |
| SCHEMBL25229692 | 0.76 | KDM4E (0.37) | KDM4EALDH1A1KMT2AMEN1HTT | |
| SCHEMBL30460853 | 0.76 | KDM4E (0.37) | KDM4EALDH1A1KMT2AMEN1HTT | |
| SCHEMBL18703689 | 0.75 | KDM4E (0.33) | CYP2D6CYP2C19KDM4EALDH1A1PDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| CN-119212988-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4450501-A1 | CDK9 INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-116354957-A | CDK9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-101489989-A | Pentadiene amide derivative | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | CYP2D6 179/4885CYP2C19 702/4885KDM4E 212/4885 |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | CYP2D6 1924/4885CYP2C19 658/4885KDM4E 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.